Cited by 121Photodynamic Therapy Research StudiesGlioma Diagnosis and TreatmentNanoplatforms for cancer theranostics

Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control

Open access
Schipmann, Stephanie, Müther, Michael, Stögbauer, Louise, Zimmer, Sebastian, Brokinkel, Benjamin, Holling, Markus, Grauer, Oliver, Suero Molina, Eric +2 more·2021·Journal of Neurosurgery

Abstract

OBJECTIVE: High-grade glioma (HGG) prognosis remains dismal, with inevitable, mostly local recurrence. Regimens for improving local tumor control are therefore needed. Photodynamic therapy (PDT) using porfimer sodium has been investigated but was abandoned due to side effects and lack of survival benefits. Intracellular porphyrins induced by 5-aminolevulinic acid (5-ALA) are approved for fluorescence-guided resections (FGRs), but are also photosensitizers. Activated by light, they generate reactive oxygen species with resultant cytotoxicity. The authors present a combined approach of 5-ALA FGR and PDT. METHODS: After 5-ALA FGR in recurrent HGG, laser diffusors were strategically positioned inside the resection cavity. PDT was applied for 60 minutes (635 nm, 200 mW/cm diffusor, for 1 hour) under continuous irrigation for maintaining optical clarity and ventilation with 100% oxygen. MRI was performed at 24 hours, 14 days, and every 3 months after surgery, including diffusion tensor imaging and apparent diffusion coefficient maps. RESULTS: Twenty patients were treated. One surgical site infection after treatment was noted at 6 months as the only adverse event. MRI revealed cytotoxic edema along resection margins in 16 (80%) of 20 cases, mostly annular around the cavity, corresponding to prior laser diffusor locations (mean volume 3.3 cm 3 ). Edema appeared selective for infiltrated tissue or nonresected enhancing tumor. At the 14-day follow-up, enhancement developed in former regions of edema, in some cases vanishing after 4–5 months. Median progression-free survival (PFS) was 6 months (95% CI 4.8–7.2 months). CONCLUSIONS: Combined 5-ALA FGR and PDT provides an innovative and safe method of local tumor control resulting in promising PFS. Further prospective studies are warranted to evaluate long-term therapeutic effects.

Integrity signals

Registry

Crossref · 10.3171/2019.11.jns192443

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a clinical trial, patients with recurrent glioblastoma underwent PpIX fluorescence-guided resection first followed immediately by PDT all after a single dose of ALA administration.

    “The use of ALA-PpIX as a fluorescent theranostic agent is well illustrated in a clinical trial where patients with recurrent glioblastoma underwent PpIX fluorescence-guided resection first followed immediately by PDT all after a single dose of ALA administration [165].”
  • Selective ALA-induced PpIX disposition in tumors made it possible for maximum safe resection of glioblastoma as well as targeting infiltrating tumor cells and unresectable tumor tissues in eloquent regions by PDT, resulting in promising progression-free survival in a disease with dismal prognosis.

    “Selective ALA-induced PpIX disposition in tumors made it possible for maximum safe resection of glioblastoma as well as targeting infiltrating tumor cells and unresectable tumor tissues in eloquent regions by PDT, resulting in promising progression-free survival in a disease with dismal prognosis.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Schipmann, S., Müther, M., Stögbauer, L., Zimmer, S., Brokinkel, B., Holling, M., Grauer, O., Suero Molina, E., Warneke, N., & Stummer, W.
Affiliations
  • Department of Neurosurgery,
  • Research Institute of Radiology (BY)
  • University Hospital Münster (DE)
Corresponding author
Schipmann, Stephanie
Venue
Journal of Neurosurgery
Published
2021-02
Volume
134
Issue
2
Pages
426-436
ISSN
  • 0022-3085 (ISSN-L)
  • 1933-0693
OpenAlex
W3001797168
Cited by
121
References
42
Citations by year
2026: 10 · 2025: 18 · 2024: 29 · 2023: 20 · 2022: 22 · 2021: 15 · 2020: 7
FWCI
9.03
Type
journal article
Language
en
Open access
Locations
  • Journal of neurosurgery (publishedVersion)
  • PubMed (publishedVersion)
Funders
Westfälische Wilhelms-Universität Münster
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
recurrent glioblastoma, 5-aminolevulinic acid, fluorescence-guided resection, photodynamic therapy, porphyrins, local tumor control, cytotoxic edema, progression-free survival, high-grade glioma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review